Bullish Stocks Gapped Higher- $MESO $VSTM $RTLR

*If You Own MESO, VSTM, RTLR Then Click Here to Join Our Community Of Traders

The Market Signal was created as a platform to help investors, if you own (NASDAQ:MESO), (NASDAQ:VSTM) or (NASDAQ:RTLR) and want to join the fastest growing community of investors on the web then sign up to the link below. Members get free access to the best investment tools in the world. Start trading like a pro today. This is a limited time offer so click the link below NOW.

(Click link above or copy, paste and hit enter in your browser for your report)

Mesoblast releases Remestemcel-L update, leadership adjustments ahead of product launch


(Click link above or copy, paste and hit enter in your browser for your report)

Mesoblast Limited (NASDAQ:MESO) gapped higher by 7.23% yesterday highlighting a potential surge.

Mesoblast announced towards the end of July that it was making some changes to its leadership structure ahead of the potential release of RYONCIL (remestemcel-L) in the U.S. the leadership changes include the appointment of as the company's new Chief Operating Officer (COO). She has been in the pharmaceutical industry for more than 25 years, during which she has garnered extensive experience. She has also been involved in key product launches in the industry. The company believes that she will be pivotal in the launch of RYONCIL.

Mesoblast previously announced that it had achieved two major milestones in the development of remestemcel-L in a Phase 3 trial treating patients with acute respiratory distress syndrome. The company also revealed that it was awaiting regulatory review and approval from the FDA.

Verastem announces its Q2 2020 financials, signs definitive agreement for COPIKTRA (duvelisib) commercialization


(Click link above or copy, paste and hit enter in your browser for your report)
Verastem Inc (NASDAQ:VSTM) stocks gaps higher by 8.11% yesterday indicating bullish potential.

Verastem announced its Q2 2020 earnings on Monday, revealing that its net product revenue for the quarter was $4.2 million. This was significantly better than the $3.0 million net product revenue that the company reported for the corresponding quarter of 2019. Its license and collaboration revenue for the quarter was $0.1 million which is the same that was reported in Q2 2019.

The company's net loss for the recent quarter was $23.0 million or $0.14 per share. This represents a lower year-over-year loss compared to the $42.2 million, or $0.57 per share net loss that the company reported in Q2 2019. The GAAP adjusted net loss for the latest quarter was $35.6 million or $0.48 per diluted share.

Verastem also announced on Monday that it recently struck a definitive agreement through which it will give Secura Bio the development and commercial rights to sell COPIKTRA across the globe. Verastem will receive $311 million as per their agreement although the upfront amount will be $70 million. The rest will be paid out as milestone payments.

Rattler Midstream announces its Q2 2020 financials


(Click link above or copy, paste and hit enter in your browser for your report)
Rattler Midstream LP (NASDAQ:RTLR) sharply gapped higher by 2.90%, signaling a potential surge.

Rattler recently announced its Q2 2020 earnings last week, revealing that its net income for the quarter was $12.5 million while its consolidated adjusted net income was $27.9 million. It also reported that its consolidated adjusted EBITDA for the quarter was $53.9 million. He company's board of directors also authorized Q2 2020 dividends at $0.29 per common share. The quarterly performance highlights improvements considering the huge negative economic performance across the industry due to the coronavirus pandemic.

Please email or contact us for any edits or errors relating to this stock market news.

If you would like information on using our press release distribution service aimed at helping investors with the best stocks to buy and how to create your own stock portfolio. We cover the US Stock Market, Canadian Stock Market, the Australian Stock Market, and other Stock Market news.

We will get back to you within 24 hours.


comtex tracking


Is there a problem with this press release? Contact the source provider Comtex at editorialpr@comtex.com.